Discontinued — last reported Q3 '21
Products & Services · Gross Profit Excluding Other Revenue
Unituxin — Gross Profit Excluding Other Revenue
United Therapeutics Unituxin — Gross Profit Excluding Other Revenue increased by 10.0% to $52.90M in Q3 2021 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2017
Last reportedQ3 2021
How to read this metric
An increase reflects improved core product performance, whereas a decrease highlights potential issues in the primary commercial business model.
Detailed definition
This metric isolates the gross profit generated strictly from core product sales, excluding ancillary income streams suc...
Peer comparison
Often referred to as 'Core Product Gross Profit' in segment reporting to distinguish from one-time licensing or milestone revenue.
Metric ID:
uthr_segment_unituxin_gross_profit_excluding_other_revenueHistorical Data
2 periods
| Q2 '21 | Q3 '21 | |
|---|---|---|
| Value | $48.10M | $52.90M |
| QoQ Change | — | +10.0% |
Range$48.10M – $52.90M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is United Therapeutics's unituxin — gross profit excluding other revenue?
- United Therapeutics (UTHR) reported unituxin — gross profit excluding other revenue of $52.90M in Q3 2021.
- What does unituxin — gross profit excluding other revenue mean?
- The profit from product sales alone, excluding non-core revenue sources.